Pharmacogenomic protocols in CNS disorders and dementia

Neurodegenerative Diseases

Volumn 7, Issue 1-3, 2010, Pages 167-169

  Cacabelos, Ramón ^a  

^a CAMILO JOSÉ CELA UNIVERSITY   (Spain)

Author keywords

Alzheimer's disease; Apolipoprotein E; Biomarkers; Pharmacogenomics

Indexed keywords

AMYLOID BETA PROTEIN; ANTIDEPRESSANT AGENT; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BENZODIAZEPINE; CENTRAL NERVOUS SYSTEM AGENTS; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; TAU PROTEIN;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; DEMENTIA; DRUG METABOLISM; GENETIC POLYMORPHISM; HAPLOTYPE; HETEROZYGOTE; HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY;

EID: 77449143860     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000289230     Document Type: Conference Paper

References (5)

1. Cacabelos R: Pharmacogenomic biomarkers in neuropsychiatry: The path to personalized medicine in mental disorders; in Ritsner MS (ed): The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes. Berlin, Springer, 2009, vol 4, pp 3-63.
2. Cacabelos R: Pharmacogenomics in Alzheimer's disease. Meth Mol Biol 2008; 448: 213-357.
3. Cacabelos R, Fernández-Novoa L, Lombardi V, Kubota Y, Takeda M: Molecular genetics of Alzheimer's disease and aging. Meth Find Exper Clin Pharmacol 2005; 27(suppl A):1-573.
4. Cacabelos R: Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics 2004; 5: 1049-1105.
5. Cacabelos R: Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease. Mol Diag Ther 2007; 11: 385-405.